Lead Product(s): Short Ragweed Pollen Allergen Extract
Therapeutic Area: Immunology Product Name: Ragwitek
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
ALK has gained approval from the US Food and Drug Administration, to expand the use of ALK’s ragweed sublingual allergy immunotherapy (SLIT) tablet RAGWITEK® (RAGWIZAX® in Europe) to include paediatric patients, down to the age of 5, with ragweed-induced allergic rhinitis.